BURNING ROCK BIOTECH LTD-ADR (BNR) Stock Price, Forecast & Analysis
USA - NASDAQ:BNR - US12233L2060 - ADR
BNR Key Statistics, Chart & Performance
The current stock price of BNR is 11.74 USD. In the past month the price increased by 46.02%. In the past year, price increased by 213.07%.
BNR Latest News, Press Relases and Analysis
BNR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About BNR
Company Profile
Burning Rock Biotech Ltd. engages in the investment of medical fields. The company is headquartered in Guangzhou, Guangdong and currently employs 674 full-time employees. The company went IPO on 2020-06-12. The firm operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.
Company Info
BURNING ROCK BIOTECH LTD-ADR
No. 5 Xingdao Ring Road North, International Bio Island
Guangzhou GUANGDONG 510005 CN
CEO: Yusheng Han
Employees: 674
Phone: 8618501641666
BURNING ROCK BIOTECH LTD-ADR / BNR FAQ
Can you describe the business of BURNING ROCK BIOTECH LTD-ADR?
Burning Rock Biotech Ltd. engages in the investment of medical fields. The company is headquartered in Guangzhou, Guangdong and currently employs 674 full-time employees. The company went IPO on 2020-06-12. The firm operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.
What is the stock price of BURNING ROCK BIOTECH LTD-ADR today?
The current stock price of BNR is 11.74 USD. The price increased by 3.71% in the last trading session.
Does BNR stock pay dividends?
BNR does not pay a dividend.
What is the ChartMill rating of BURNING ROCK BIOTECH LTD-ADR stock?
BNR has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of BURNING ROCK BIOTECH LTD-ADR (BNR)?
BURNING ROCK BIOTECH LTD-ADR (BNR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.99).
What is BURNING ROCK BIOTECH LTD-ADR worth?
BURNING ROCK BIOTECH LTD-ADR (BNR) has a market capitalization of 120.44M USD. This makes BNR a Micro Cap stock.
BNR Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to BNR. When comparing the yearly performance of all stocks, BNR is one of the better performing stocks in the market, outperforming 97.81% of all stocks.
BNR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BNR. BNR has a bad profitability rating. Also its financial health evaluation is rather negative.
BNR Financial Highlights
Over the last trailing twelve months BNR reported a non-GAAP Earnings per Share(EPS) of -1.99. The EPS increased by 96.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17% | ||
| ROE | -24.86% | ||
| Debt/Equity | 0 |
BNR Forecast & Estimates
For the next year, analysts expect an EPS growth of -277.41% and a revenue growth 48.35% for BNR